Hormones and Decision Making

Dyssocial Behavior Clinical Trial

Official title:

Hormones and Decision Making

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04865562
• Other study ID #: 2015-02-0011
• Status: Completed
• Phase: Phase 4
• Start date: March 1, 2015
• Est. completion date: September 1, 2016

Study information

• Verified date: April 2021
• Source: University of Texas at Austin
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An investigation of the neuropsychological processes underlying ethical decision making.

Description:

This study will investigate the influence of reward sensitivity on cheating behavior via experimental manipulation of reward sensitivity using testosterone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: September 1, 2016
• Est. primary completion date: May 1, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 25 Years

Eligibility

Inclusion Criteria:

• males between 18 and 25

Exclusion Criteria:

• recruitment will be limited to male participants between 18 and 25 years who have no current conditions that would preclude the use of testosterone. Specific exclusion criteria are:

• women of all ages

• males younger than 18 years and older than 25 years

• self-report discomfort with ingestion of testosterone for the purpose of this study

• body mass index lower than 18 or higher than 27

• prior diagnosis of major depression, posttraumatic stress disorder, phobia, anxiety disorder, or other psychiatric conditions

• first-degree relatives diagnosed with a psychiatric disorder

• presence of a medical condition that would preclude the use of testosterone

• use of medications that would preclude the use of testosterone

• consumption of more than 5 cigarettes a day

• current use of testosterone enhancing products, such as gels, creams, and injections

Related Conditions & MeSH terms

• Antisocial Personality Disorder
• Dyssocial Behavior

Intervention

Drug:
• testosterone propionate
1mg/0.1mL solution, to be administered intranasally
• 0.5% cholorbutanol, saline
125 mg 0.5% cholorbutanol, 50mg saline

Locations

Country	Name	City	State
United States	Robert Josephs	Austin	Texas

Sponsors (1)

Lead Sponsor	Collaborator
University of Texas at Austin

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure of ethical behavior - Cheating rate defined as the Average number of 'heads' coin flips participants claim to have obtained	drug administration following by behavioral outcome. Specifically, participants will have the opportunity to predict the outcome of a series of coin flips. To obtain a measure of ethical behavior, participants will have the opportunity to cheat by over-reporting their prediction accuracy.	90 minutes